Investigational / not FDA-approved

GHRP-6

Classic Bowers GH-releasing hexapeptide — investigational; not FDA-approved.

Editorial review:

What evidence says

Evidence snapshot

This drawer marks papers. It is not a plan, a dose, or a source. A paper is a bounded report. It is not a protocol. Grades name the object. They are not a safety rating.

Identity lock. GHRP-6 is the classic synthetic GH-releasing hexapeptide His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂. PubChem CID 4345065; formula C46H56N12O6; MW ~873.0; CAS 87616-84-0. PubChem synonym noise may list unrelated strings (including “GHRP-2 Acetate”-style errors) — trust sequence/CAS/CID, not synonym spam. It is not hexarelin (2-methyl-Trp analog), not GHRP-2/pralmorelin, and not ipamorelin. Foundational Bowers-line discovery and human synergy-with-GHRH work define this object. No approved bodybuilding indication. Off-label does not apply. There is no label to be off of.

Bottom line

Strong foundational human and preclinical GH-secretagogue literature: GHRP-6 releases GH, acts synergistically with GHRH in many settings, and entered adult GHD diagnostic algorithms (alone or with GHRH) as an alternative stimulus to insulin tolerance testing in research/clinical endocrinology. Later organ-failure and animal models are not physique grades. Anti-doping detection papers are not efficacy. Keep hexarelin / GHRP-2 / ipamorelin out of this drawer’s paper grades.

Papers

Discovery / early human — Bowers line

PMID 6714155 — Bowers 1984

Tested: in vitro and in vivo activity of a synthetic hexapeptide that specifically releases GH from the pituitary (foundational GHRP object matching the GHRP-6 sequence family).

Does not show: modern outpatient anti-aging efficacy, or identity with GHRP-2/hexarelin.

PMID 2108187 — Bowers 1990

Tested: GHRP stimulates GH release in normal men and acts synergistically with GHRH.

Does not show: a chronic therapy indication or body-composition RCT.

PMID 1730807 — Bowers 1992

Tested: oral administration of the GH-releasing hexapeptide (His-DTrp-Ala-Trp-DPhe-Lys-NH₂) in normal men and short-statured children; GH and peptide levels.

Does not show: approved oral secretagogue product for wellness use, or hexarelin results.

PMID 8370708 — Alster 1993

Tested: GH response to GHRP (His-DTrp-Ala-Trp-DPhe-Lys-NH₂), GHRH, and TRH in men (specificity / stimulus characterization).

Does not show: chronic treatment benefit.

Human — stimulus physiology / aging / pathology

PMID 8421084 — Peñalva 1993

Tested: effects of GHRH, atropine, pyridostigmine, or hypoglycemia on GHRP-6-induced GH secretion in man (mechanistic endocrine physiology).

Does not show: a therapeutic body-composition claim.

PMID 7734029 — Micic 1995

Tested: GH secretion after GHRP-6 or GHRH+GHRP-6; whether responses decline in late adulthood.

Does not show: anti-aging treatment efficacy.

PMID 7883854 — Popovic 1995

Tested: blocked GHRP-6-induced GH secretion and loss of GHRP-6+GHRH synergy in hypothalamic-pituitary disconnection / related pathology contexts.

Does not show: recreational use guidance; diagnostic/pathophysiology object.

Human — diagnostic GHD testing

PMID 8887178 — Pombo 1996

Tested: GHRP-6 test in the diagnosis of GH deficiency.

Does not show: chronic replacement with GHRP-6 as standard of care, or physique outcomes.

PMID 11980622 — Petersenn 2002

Tested: diagnosis of adult GH deficiency with GHRP-6 alone or combined with GHRH versus insulin tolerance test.

Does not show: approved long-term secretagogue therapy for non-GHD adults.

PMID 15817913 — Haijma 2005

Tested: GHRH/GHRP-6 test for GHD diagnosis in elderly or severely obese men.

Does not show: obesity treatment with GHRP-6.

Context — organ-failure model / detection

PMID 16417467 — Cibrián 2006

Tested: GHRP-6 for prevention of multiple organ failure (translational/clinical exploratory object — not a gym indication).

Does not show: bodybuilding efficacy or an approved ICU labeling grade in this pack’s framing.

PMID 25809000 — Cox 2015

Tested: detection of GHRP-2 and GHRP-6 in athlete urine.

Does not show: therapeutic benefit.

What is not established

Approved anti-aging, muscle-building, or fat-loss indications. Equivalence to hexarelin, GHRP-2, or ipamorelin. Chronic unsupervised outpatient use as “therapy.” Product identity for unlabeled vials. Diagnostic GH release is not a physique protocol and is not graded as one.

Selected sources

6714155 2108187 1730807 8370708 8421084 7734029 7883854 8887178 11980622 15817913 16417467 25809000

What people discuss

Reported experiences

Reported topics are not established benefits.

Watch for

Risks and unknowns

Context matters. Approval of one medicine, formulation, or use does not establish approval of products sold online or other uses. This page is educational and does not provide dosing or treatment advice.

Member discussion

Compare experiences with care.

Before posting: Describe firsthand observations and uncertainty. Do not prescribe, arrange transactions, or post private health information.

◎Verified members

Join the discussion

Verified members can contribute to compound conversations.

No approved member reports yet. Thoughtful first contributions are welcome.